medigraphic.com

2000, Number 2

<< Back Next >>

Rev Mex Anest 2000; 23 (2)

Clinical evaluation of Mivacurium

Valencia TMA, Partida RA

Language: Spanish
References: 24
Page: 83-88
PDF size: 993.62 Kb.


ABSTRACT

Background: This study was designed in order to evaluate a new short-acting non-depolarizing neuromuscular blocking agent, Mivacurium (MIV), in 60 patients with the approval of the Hospital´s Ethics Committee. Material and Methods: Sixty patients non-medicated, ASA physical status I-II, programmed for elective surgery were allocated in for groups age-relatives: 4-16 years old in group A, 17-30 yrs in group B. 31-59 years old in group C and oldest to 60 years in group D, and they were anesthetized with O2 + N2O + Halothane. The anesthesia induction was done with Thiopental (5 mg/kg) and MIV at 0.15 mg/kg; tracheal intubation was done at 2.30 min after MIV application and the grade of muscular relaxation for intubation, the time for spontaneous recovery of 95% of train of four in ulnar nerve and time for spontaneous ventilation, cardiovascular effects and complications were evaluated. Results: The grade of muscular relaxation for the tracheal intubation were excellent in 49 cases (81.66%) and good in 11 cases (18.33%), the time of spontaneous recovery of 95% of the T4 in ulnar nerve was 10.05 min in group A, 11.32 min in group B, 14.27 min in C and 16.0 min in group D. The spontaneous ventilation was present in all cases 2-3 min before achieved 95% of T4. There were significative differences between groups A-C, A-D, B-C and B-D (p ‹ 0.05), but not between A-B and C-D. All the patients showed light to mild bradycardia and hypotension in most of cases. There were two cases of toracoabdominal rash less than five min of duration and disappeared with out treatment. Conclusions: The MIV in dose of 0.15 mg/kg at 2.30 min from intravenous application allowed a successful tracheal intubation with out complications and with a spontaneous recovery of muscular relaxation in less than 20 minutes.


REFERENCES

  1. Maehr RB. Autonomic and neuromuscular effects of mivacurium and isomers in cats. Anesthesiology 1991;75:A772.

  2. Debros P. Pharmacokinetics and pharmacodynamics of BW B1090U in healthy surgical patients receiving N2O/O2 isoflurane anesthesia. Anesthesiology 1987;67:A609.

  3. Phillips L. Mivacurium stereoisomer pharmacodynamics. Pharma Res 1992;9:S-356.

  4. Savarese JJ. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). Anesthesiology 1988;68:723-32.

  5. Savarese JJ. The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Anesthesiology 1989;70:386-94.

  6. Savarase JJ. Sixty-second tracheal intubation with BWB1090U after fentanyl thiopental induction. Anesthesiology 1987;67:A351.

  7. Savarase JJ. The newer muscle relaxants, 1991 ASA Annual Refresher Course Lectures, Las Vegas, NV 521.

  8. Lien CA. Muscle relaxants: the next generation. 1995 ASA Annual Refresher Course Lectures, Atlanta GA, 321.

  9. Goodhill DR. Neuromuscular and clinical effects of mivacurium chloride in healthy adult patient during nitrous oxide-enflurane anesthesia. Br J Anesth 191;67:289-95.

  10. Miller RD. The rational use muscle relaxants. 1991 ASA Annual Refresher Course Lectures. Las Vegas NV, 223.

  11. Cook DR. In Vitro metabolism of mivacurium chloride (BW B1090U) and succinycholine. Anesth Analg 1989;68:452-6.

  12. Lien CA. The Pharmacokinetics and pharmacodynamics of the stereoisoners of mivacurium in patients receiving nitros oxide/opioid/barbiturate anesthesia. Anesthesiology 1994;80:1296-302.

  13. Brandom BW. Muscle Relaxants in infants and children-How they differ from adults. 1995; ASA Refresher Course Lectures. Atlanta GA, 22414.

  14. Caldwell JE. Comparison of the neuromuscular block induced by mivacurium, suxamethonium or atracurium during nitrous oxide-fentanyl anaesthesia. Br J Anaesth 1989;63:393-9.

  15. Ali HH. Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: comparasion with vecuronium and atracurium. Br J Anaesth 1988;61:541-6.

  16. Koscielniak-Nielsen SJ. Onset of maximum neuromuscular block following succinylcholine or vecuronium in four age groups. Anesthesiology 1993;79:229-34.

  17. Woelfel SK. Dose-response raltionship of mivacurium chloride in infants during nitrous oxide-halothane anesthesia. Anesthesiology 191;75:A775.

  18. Van Lithout LEH. Age differences in magnitude and complete recovery of mivacurium induced neuromuscular block. Anesthesiology 1995;83:A897.

  19. Brandom BW. Neuromuscular blocing drugs: Developments in pediatric anesthesia. Anesth Clin North Am 1991;9:781-800.

  20. Brandom BW. Mivacurium infusion requeriments in pediatric surgical patients during nitrous oxide-halothane and during nitrous oxide-narcotic anesthesia. Anesth Analg 1990;71:16-20.

  21. Woelfel SK. Clinical pharmacology of mivacurium in pediatric patients less than two old during nitrous oxide-narcotic anesthesia. Anesth Analg 1993;77:713-20.

  22. Bevan JC. Dose responses for neostigmine and edrophonium as antagonists of mivacurium in adults and children. Anesthesiology 1996;84:354-61.

  23. Meteroja OA. Pharmacodynamics of mivacurium in children using a computer-controlled infusion. Br Anesth 1993;71:232-7.

  24. Naguib M. Enzymatic versus pharmacologic antagonism of profound mivacurium-induced neuromuscular blockade. Anesthesiology 1996;84:1051-9.




2020     |     www.medigraphic.com